Wasatch Advisors Inc. trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 5.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 437,304 shares of the medical device company’s stock after selling 25,940 shares during the quarter. Wasatch Advisors Inc. owned 1.27% of AtriCure worth $10,605,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of ATRC. Neuberger Berman Group LLC increased its position in shares of AtriCure by 45.5% during the second quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock valued at $19,993,000 after acquiring an additional 257,949 shares during the last quarter. FMR LLC increased its position in shares of AtriCure by 2.7% during the first quarter. FMR LLC now owns 4,950,000 shares of the medical device company’s stock valued at $94,793,000 after acquiring an additional 130,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of AtriCure by 5.7% during the first quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock valued at $26,695,000 after acquiring an additional 75,266 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of AtriCure by 131.9% during the first quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock valued at $2,145,000 after acquiring an additional 63,711 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in AtriCure in the second quarter worth $1,120,000. 82.11% of the stock is owned by institutional investors.
In other news, Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the sale, the director now directly owns 29,967 shares in the company, valued at approximately $671,260.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.
WARNING: “AtriCure, Inc. (ATRC) Shares Sold by Wasatch Advisors Inc.” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/10/16/atricure-inc-atrc-shares-sold-by-wasatch-advisors-inc.html.
A number of research firms have issued reports on ATRC. Zacks Investment Research raised AtriCure from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. BidaskClub downgraded AtriCure from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Stifel Nicolaus reissued a “buy” rating and issued a $25.00 target price on shares of AtriCure in a research report on Sunday, July 30th. Canaccord Genuity reissued a “buy” rating and issued a $28.00 target price on shares of AtriCure in a research report on Monday, October 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $26.00 target price (up from $25.00) on shares of AtriCure in a research report on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. AtriCure has an average rating of “Buy” and an average target price of $25.83.
AtriCure, Inc. (NASDAQ ATRC) traded up 1.30% during mid-day trading on Monday, reaching $22.57. The company’s stock had a trading volume of 8,693 shares. The firm’s market cap is $774.92 million. The company has a 50-day moving average price of $21.85 and a 200-day moving average price of $21.95. AtriCure, Inc. has a 12-month low of $14.78 and a 12-month high of $25.18.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The firm had revenue of $45.23 million during the quarter, compared to analyst estimates of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. AtriCure’s revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS. On average, equities research analysts expect that AtriCure, Inc. will post ($0.95) earnings per share for the current year.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.